Using sequencing techniques, researchers associated 51 mutations in mitochondrial DNA with amyotrophic lateral sclerosis (ALS ...

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

ALS is a neurodegenerative disease that progressively paralyzes individuals as the brain loses the ability to communicate with the muscles. People living with ALS often experience a swift decline in ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that ...

Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...

Amyotrophic Lateral Sclerosis (ALS) Treatment Market size was valued at USD 713.3 million in 2023 and is expected to grow at a CAGR of 5.5% from 2024 to 2032. This growth is driven by the ...

Tal Newberry passed from Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease on Christmas Day in ...

Report Ocean, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Amayotrophic Lateral Sclerosis (ALS) Market size by value at USD 902 million in 2023.

Scientists have identified a relationship between ancient viral DNA and susceptibility to neurodegenerative diseases like ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that is marked by fasciculation, spasticity and progressive weakness of muscles, and results in difficulty speaking ...

Using sequencing techniques, researchers associated 51 mutations in mitochondrial DNA with amyotrophic lateral sclerosis (ALS), an incurable degenerative neurological disorder that leads to muscle ...